Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $1.0 million.

  • Axsome Therapeutics' Treasury Shares rose 1197.71% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 1197.71%. This contributed to the annual value of $906944.0 for FY2024, which is 1278.29% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Treasury Shares is $1.0 million, which was up 1197.71% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Treasury Shares peaked at $1.0 million during Q2 2025, and registered a low of $667366.0 during Q1 2022.
  • In the last 4 years, Axsome Therapeutics' Treasury Shares had a median value of $804150.0 in 2023 and averaged $838997.4.
  • Its Treasury Shares has fluctuated over the past 5 years, first soared by 1794.64% in 2023, then soared by 764.66% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Treasury Shares (Quarter) stood at $686375.0 in 2022, then rose by 17.16% to $804150.0 in 2023, then increased by 12.78% to $906944.0 in 2024, then rose by 11.03% to $1.0 million in 2025.
  • Its Treasury Shares was $1.0 million in Q3 2025, compared to $1.0 million in Q2 2025 and $993202.0 in Q1 2025.